Prof. Xinbing Sui | Anticancer Drug | Best Researcher Award

Professor at Hangzhou Normal University, China

Prof. Xinbing Sui is a distinguished Professor and Chief Physician in the Department of Medical Oncology at Hangzhou Normal University, China. He holds dual doctoral degrees (Ph.D. in Oncology and M.D. in Traditional Chinese Medicine) and completed a prestigious research fellowship at Harvard Medical School.

Profile:

• Scopus

🎓 Academic Background:

• Ph.D. in Oncology, Zhejiang University

• M.D. in Traditional Chinese Medicine & Surgery, Zhejiang Chinese Medical University

• B.S. in Pharmaceutical Engineering, Shandong Chinese Medical University

• Research Fellow, Harvard Medical School (2016–2017) 🇺🇸

🏥 Current Roles:

• Chief Physician, Medical Oncology, Affiliated Hospital of Hangzhou Normal University

• Dean, Department of Medical Oncology

• Professor, College of Pharmacy, Hangzhou Normal University

🔬 Research Interests:

• Cancer drug resistance mechanisms

• Autophagy & ferroptosis in cancer (non-apoptotic cell death)

• Nanomedicine & traditional Chinese medicine in oncology

• Natural compounds & immunotherapy

📚 Scientific Impact:

• 240+ high-impact publications, including:

  • Signal Transduction and Targeted Therapy (IF: 52.7)

  • Autophagy, Cancer Letters, PNAS, Adv Sci, Theranostics, Nucleic Acids Research

• First/Corresponding Author on most papers

• Highly Cited Researcher 2024 (Pharmacology & Toxicology)

• World’s Top 2% Scientist (2023 & 2024)

💡 Innovation & Patents:

• Holder of multiple patents for:

  • Liposome drug delivery

  • TCM-based anticancer formulations

  • Combination therapies

🧬 Notable Research Projects:

• PI/Co-PI in projects funded on:

  • Overcoming chemoresistance in colorectal and lung cancer

  • Role of autophagy, ferroptosis, and metabolism in tumor suppression

  • KDM6A regulation in bladder cancer

  • TCM compounds like Elemene and Erianin in cancer therapy

🏅 Honors & Memberships:

• 🌟 “35 Under 35” Distinguished Oncologist of China (2017)

• 🏅 Zhejiang University Rising Star in Oncology

• 📘 Member of:

  • China Anticancer Association

  • Zhejiang Cancer Chemotherapy Association

  • Zhejiang Anticancer Immune Association

🌐 Collaborations & Global Reach:

• Actively collaborates with international researchers across the USA, EU, and Asia

• Works at the intersection of basic science and translational medicine

• Contributed to machine learning models for cancer diagnostics

📊 Citation Metrics:

• Total Citations: 18,158

• Citing Documents: 16,725

• h-index: 46

• Total Publications: 136

Publication Top Notes:

1. Construction of machine learning-based models for screening the high-risk patients with gastric precancerous lesions
   Chinese Medicine (United Kingdom), 2025

2. Synergistic Strategies for Lung Cancer Immunotherapy: Combining Phytochemicals and Immune-Checkpoint Inhibitors (Review)
   [Journal unspecified], 2025

3. PLA2G16 expression predicts prognosis and gemcitabine sensitivity in patients with pancreatic cancer
   PeerJ, 2025